Chloroquine as an antimalarial: what it is, how it works, and key facts

What chloroquine is and why it matters for malaria

Chloroquine is a synthetic antimalarial drug long used to both prevent and treat infection by Plasmodium species transmitted by mosquitoes. Introduced as a safer alternative to earlier quinine-based therapies, chloroquine became a cornerstone of malaria control in many regions because of its reliability, low cost, and favorable pharmacology. It primarily targets the blood stages of the parasite, reducing parasite biomass and symptoms while also preventing infection in travelers when taken as directed for prophylaxis. Over time, widespread use led to varying degrees of parasite resistance, shaping how clinicians choose antimalarials today.

This profile explains how chloroquine works, when it is still effective, how to use it safely for treatment and prevention, and what to consider when resistance is present. The information is intended for clinicians, travelers, and public health professionals seeking a durable, practical understanding.

How chloroquine works in the body

Mode of action against Plasmodium

Chloroquine interferes with the parasite’s ability to digest hemoglobin inside red blood cells. After the parasite digests hemoglobin, it produces heme, a toxic byproduct; under normal conditions the parasite converts heme into non-toxic hemozoin crystals. Chloroquine raises the pH within the parasite’s digestive vacuole, weakening enzymes needed for this detoxification and allowing heme to accumulate to lethal levels. This action primarily kills blood-stage parasites responsible for clinical symptoms rather than liver-stage forms that initiate infection.

Pharmacokinetics and dosing considerations

Chloroquine is well absorbed after oral administration, reaches high concentrations in blood and tissues, and has a large volume of distribution, including into the liver, spleen, and bone marrow. Its long half-life allows once-weekly dosing for malaria prophylaxis and relatively straightforward treatment schedules. The drug is extensively metabolized in the liver and excreted mainly via the kidneys, so dose adjustments are necessary in renal impairment and caution is warranted in people with liver disease. Gastrointestinal symptoms, headache, and dizziness are among the most common side effects; serious effects such as retinopathy or cardiomyopathy are rare at standard antimalarial doses but increase with long-term use.

Historical role and global impact

Chloroquine emerged in the 1940s and rapidly replaced quinine and related drugs because it was more effective, better tolerated, and easier to administer. It helped shrink malaria-endemic regions and supported public health campaigns in the mid-20th century. Its value extended beyond malaria as an immunomodulatory agent in rheumatology, although such use is separate from antimalarial indications. During campaigns that sought to interrupt transmission in formerly endemic areas, chloroquine played a prominent, though now-limited, role when local parasite sensitivity remained high.

Current patterns of efficacy and resistance

Parasite resistance to chloroquine emerged decades ago in parts of South America, Southeast Asia, and particularly sub-Saharan Africa, where it rendered the drug largely ineffective for treatment. Because of this, many national malaria programs now recommend alternative first-line treatments, typically artemisinin-based combination therapies (ACTs), for uncomplicated Plasmodium falciparum infection. Chloroquine may still be recommended for treatment in regions where Plasmodium vivax and Plasmodium ovale remain fully susceptible, and it remains a key option for prophylaxis in areas without significant resistance, provided local guidance is followed. Understanding local resistance patterns is essential for clinicians and travelers alike.

Chloroquine for malaria prophylaxis

When and where it remains suitable

Chloroquine is recommended for malaria chemoprophylaxis only in areas where Plasmodium falciparum and Plasmodium vivax are known to be fully susceptible. Travelers to such regions can take chloroquine once weekly, beginning before travel, continuing during exposure, and for four weeks after leaving the area. Adherence to the weekly schedule is critical, and missed doses raise the risk of infection. In areas with documented chloroquine resistance, alternative prophylactic regimens should be used to ensure adequate protection.

Practical advice for travelers

• Confirm local resistance patterns using current national or regional guidance before starting prophylaxis.
• Take the exact dose on the correct weekly schedule; use alarms or calendar reminders if necessary.
• Report persistent vomiting or severe side effects to a clinician promptly; alternative medicines may be needed.
• Continue the post-travel course for the recommended duration even if you feel well to prevent late illness.

Safety, adverse effects, and contraindications

Common and serious adverse effects

Most people tolerate chloroquine at antimalarial doses, but common side effects can include nausea, vomiting, headache, and itching. Neuropsychiatric effects such as dizziness or malaise may occur. Rare but serious effects include retinopathy with long-term use, cardiomyopathy, and severe skin reactions. Because chloroquine can prolong the QT interval, concurrent use with other QT-prolonging drugs should be evaluated carefully. People with known hypersensitivity to chloroquine or related compounds, or certain eye and cardiac conditions, may be advised against its use.

Special populations and drug interactions

• Pregnancy: Chloroquine is generally considered compatible with pregnancy in areas where it remains effective for prophylaxis or treatment, but risk-benefit discussion with a clinician is advised.
• Renal impairment: Dose adjustment or alternative therapy is often recommended due to reduced drug clearance.
• Drug interactions: Caution is advised with medicines that prolong QT, anticonvulsants, and drugs metabolized by similar liver pathways; clinicians should review all medications.

Key facts at a glance

Choosing antimalarials in the modern context

Current malaria management emphasizes region-specific strategies based on parasite susceptibility, vector behavior, and drug safety profiles. Chloroquine retains value where susceptibility is confirmed, particularly for P. vivax in some regions, but ACTs are preferred first-line treatment for falciparum malaria in most endemic areas. Clinicians consider local resistance maps, patient comorbidities, and potential drug interactions when selecting therapy, while travelers rely on up-to-date guidance for prophylaxis decisions.

Bottom line

Chloroquine remains a historically important antimalarial with clear pharmacological advantages when used in susceptible settings. Its role today is carefully delineated by resistance patterns, with alternative therapies preferred in many high-burden regions. Understanding when chloroquine is appropriate, how it works, and what safety considerations apply enables informed decisions for malaria prevention and treatment.